Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
Authorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney’s office said Thursday.
More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.
The market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
The proposal garnered support from the owners of 62 percent of Eli Lilly’s outstanding shares. To pass, the proposal needed approval from the owners of 80 percent of Lilly’s shares.
Endocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian cancer treatment with pharmaceutical giant Merck & Co.
Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
Express Scripts Inc.’s $29.1 billion bid for rival drug benefit manager Medco Health Solutions Inc. won unconditional approval from U.S. antitrust regulators, clearing the way to create the biggest manager of prescription-drug benefits for corporate and government clients.
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
Express Scripts Inc.’s bid to acquire Medco Health Solutions Inc. and create the largest U.S. pharmacy-benefits manager may be delayed by a lawsuit being considered by five states.
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
Two pharmacy groups opposing Express Scripts Inc.’s proposed acquisition of Medco Health Solutions Inc. said they were asked by the U.S. Federal Trade Commission to suggest ways to revise the $29.1 billion deal so it wouldn’t harm competition.
Endocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced Monday, clearing away a hurdle to getting the drug approved in Europe.
Indianapolis-based Lilly pleaded guilty to one violation of the Food, Drug and Cosmetic Act on Thursday and agreed to pay $1.42 billion to settle both that criminal charge as well as civil lawsuits in which it did not admit wrongdoing.
Doctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
Eli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
